TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Relationship Between Constitutional Varus Knee and Patellofemoral Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patellofemoral pain during physical activities such as running, jumping, squatting, and going up or down stairs for at least 4 weeks.~* The onset of pain is required to be atraumatic in nature.~* Exhibit two of the following clinical criteria on assessment: pain on direct compression of the patella against the femoral condyles with the knee in full extension, tenderness of the posterior surface of the patell on palpation, pain on resisted knee extension, and pain with isometric quadriceps muscle contraction against suprapatellar resistance with the knee in 15° of flexion.~* Negative findings in the examination of knee ligaments, menisci, bursae, synovial plicae, Hoffa's fat pad, iliotibial band, and the hamstring, quadriceps, and patellar tendons and their insertions.~Exclusion Criteria:~* With patellofemoral instability, or With other knee diagnoses.~* Any previous surgery or severe trauma in the affected limb.~* Inflammatory joint disease or tumors in the affected limb.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- The study group (Type: None): The participants with patellofemoral pain.
- The control group (Type: None): The participants without patellofemoral pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children less than 18 years of age and at least 6 months post AVSD repair or reoperation~* At least moderate MR~* Asymptomatic or minimally symptomatic, defined by Ross Heart Failure Class I or II~* Atrioventricular synchrony (paced or intrinsic)~Exclusion Criteria:~* Tetrology of Fallot, total or partial anomalous venous connection~* More than trivial MS or outflow obstruction~* Other sources of LV volume overload~* Hypertrophic obstructive cardiomyopathy~* Significant residual coarctation

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): Ace inhibition (enalapril)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* documented HIV infection~* presence of HIV associated neurocognitive disorders requiring a lumbar puncture for clinical reasons~* treatment or qualifying to be treated with a HIV therapy including darunavir/r (800/100 mg once daily)~* ability to comply with the study requirements~* informed consent~Exclusion Criteria:~* conditions which disrupt the blood-brain barrier and thereby impact the entry of drugs in the brain (meningitis, meningoencephalitis, multiple sclerosis, progressive multifocal leucoencephalopathy)~* co-medications inhibiting/inducing P-glycoprotein and BCRP~* co-medications inhibiting/inducing cytochrome P450 isoenzyme 3A4 (CYP3A4)~* non adherence to Treatment~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darunavir/ritonavir vs cobicistat (Type: EXPERIMENTAL): All HIV infected patients will be treated with a darunavir/ritonavir (800/100 mg) once daily containing regimen. Darunavir/ritonavir concentrations will be measured simultaneously in CSF and plasma after 1 month of treatment. The treatment will be switched to darunavir/cobicistat (800/150 mg) once daily and darunavir/cobicistat levels will be measured in CSF and plasma after 1 month of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18-80 years old, male and female~2. Without anti-cancer treatment before randomization, ECOG score 0-2~3. Estimate to bear at least 4 cycles chemotherapy treatment with normal function of heart, lungs, liver and kidneys.~4. Survival expectation ≥6 months~5. Signed Informed Consent Form, willing to follow all study procedures~Exclusion Criteria:~1. Received chemotherapy treatment within 4 weeks before randomization.~2. Current peripheral neuropathy(by chemotherapy, diabetes mellitus, alcoholic disease) and relative symptoms with relevant treatment.~3. Concurrent treatment within 30 days after randomization with the following drugs: Calcium-Magnesium injection, glutathione, and similar ingredients with PerOx Quench (such as polyene phosphatidyl choline).~4. Laboratory tests found not suitable for chemotherapy patients (Absolute neutrophil count \<2.0×10\*9/L\<2,000/mm3\>; or platelet count\<100× 10\*9/L\<100,000/mm3\>; or hemoglobin \<10/dl; or serum total bilirubin \>2 Upper Limit Of Normal (ULN), alanine aminotransferase (ALT)/aspartate aminotransferase (AST)\>3 Upper Limit Of Normal (ULN); or serum creatinine \>1.5 Upper Limit Of Normal (ULN) \<or creatinine clearance rate~   ≤60ml/min\>）.~5. Pregnancy, lactation and reluctant to using contraception women.~6. Patients with symptomatic brain metastases and other mental disorders could not be self assessment.~7. Alcohol and/or drug abuse or doctors determine compliance's claim.~8. Within a month in other clinical trial subjects.~9. Once into the group of this study, or random within eight weeks before using this product.~10. personnel involved this study.~11. Not completed independent self assessment of patients.~12. Other researchers determine does not fit to participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PerOx Arm (Type: EXPERIMENTAL): PerOx Quench arm 4g/sachet each time by water, q6h
- Comparative Arm (Type: PLACEBO_COMPARATOR): PerOx Quench placebo 4g/sachet each time by water, q6h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older;~* Pathological diagnosis of patients with stage II, III A primary NSCLC;~* R0 resection has been accepted;~* Received adjuvant chemotherapy or adjuvant chemotherapy for the first time after surgery;~* Informed consent has been signed.~Exclusion Criteria:~* Incorporation of other malignant tumors (such as leukemia, liver cancer, etc.)；~* Patients with unclear pathological types；~* Patients with unclear pathological staging；~* Preserved Shenlingcao Oral Liquid before R0 resection surgery；~* Received immunotherapy or targeted therapy before R0 resection surgery；~* Radiotherapy and chemotherapy before R0 resection surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exposure group (Type: None): Exposure group patients are those who voluntarily choose to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy. Jiangzhong Group will donate the first 30 bottles of medicine, and afterwards, patients may purchase if they still need to take it. The length of time and dose of Shenlingcao Oral Liquid are unlimited and other adjunctive treatments may be used at the same time.
- Control group (Type: None): Control group patients are those who voluntarily choose not to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Artegraft Versus Propaten Dialysis Grafts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age~* Candidate for hemodialysis~* Not a candidate for native AV fistula~* In need of a new AV graft in the upper arm location~* Artery and vein \> 3mm.~* Medically stable and have a life expectancy of ≥ 12 months~* The patient or legal guardian understands the study and is willing to comply with the requirements.~Exclusion Criteria:~* \< 18 years of age~* Current history or within 6 months of IV drug abuse~* Chronic hypotension (\<100 mm systolic pressure) not responsive to treatment~* Pregnant or lactating~* Known hypercoagulable state~* Requires only a revision of an existing graft~* Receiving artery or vein is less than 3 mm in diameter at the time of implantation~* Known axillary/subclavian occlusion or stenosis that has not been treated~* Known or suspected systemic infection~* Heparin sensitivity (known HIT)~* Enrolled in another investigational study.~* Subject has more than 1 graft in target limb.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artegraft (Type: ACTIVE_COMPARATOR): Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
- Propaten (Type: ACTIVE_COMPARATOR): Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ovarian Freezing Before Cancer Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female patient between the ages of 18 and 42 years.~* In need of imminent cancer treatment, including surgery, chemotherapy or radiation therapy, which is viewed as likely to result in a permanent and complete loss of subsequent ovarian function or have a health condition that will result in premature ovarian failure. These include, but are not limited to: abdominopelvic irradiation, total body irradiation, alkylating-intensive chemotherapy, and removal of ovaries as part of their cancer treatment.~* Reasonably good health.~* Two ovaries.~* Able to defer definitive cancer therapy for approximately 3 days until the patient recovers from laparoscopic oophorectomy.~Exclusion Criteria:~* Patients considered as high risk for surgical complications will be excluded from the research protocol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Role of C-HAM in the Surgical Repair of Peroneal Tendons: An Infrared Thermography Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients requiring surgical repair of the peroneal tendon~2. Patients who voluntarily consent to research participation~3. Patients over the age of 18~Exclusion Criteria:~1. Patients who display a high surgical risk as determined by the investigative surgeon~2. Previous surgical repair of the peroneal tendon less than 2 years prior to surgery~3. Peroneus brevis tears in zone 3 or 4 that may hinder recovery in the investigator's opinion~4. Patients with allergy or history of drug reactions to Ciprofloxacin or Amphotericin B~5. Patients who are pregnant or breast feeding.~6. Patients who have had a clinically diagnosed autoimmune disease~7. Patients who are unwilling to restrict pre and postoperative anti-inflammatories with the exception of ecotrin 325 mg QD for DVT prophylaxis during the postoperative immobilization period~8. Patients with an active infection~9. Patients who have a medical history that would likely make the patient an unreliable research participant~10. Patients requiring surgical repair of the peroneus longus tendon

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clarix™1k graft (Type: EXPERIMENTAL): Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
- Control arm without Clarix™1k graft (Type: NO_INTERVENTION): Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Interested in resuming or continuing sexual activity~* Greater than 12 months since last menstrual cycle or prior bilateral oophorectomy~* Dyspareunia as a vulvovaginal atrophy symptom~* Normal mammogram within 12 months prior to entry into the study~Exclusion Criteria:~* History or suspicion of breast carcinoma~* History of hormone-dependent tumor~* Genital bleeding of unknown cause~* Ongoing vaginal infection~* History of cerebrovascular accident (CVA), myocardial infarction (MI) or heart disease~* Uncontrolled hypertension (HTN) over 160/100~* Serious disease or chronic condition that may prevent completion of study~* Body Mass Index (BMI) over 40~* Hypercoagulable state, or currently on anticoagulant therapy~* Use of any exogenous sex hormone within three months from study entry, or during the study~* Pelvic surgery within the last 12 months

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ospemifene (Type: EXPERIMENTAL): Women randomized to this arm will receive 60mg oral ospemifene, taken daily, for 12 weeks
- Estrogen (Type: ACTIVE_COMPARATOR): Women randomized to this arm will receive 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Remifentanil on Hemodynamic Stability During Placement of a Mayfield Head Fixation Device for Craniotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult non-pregnant patients~* undergoing general anesthesia for a craniotomy~* requiring a Mayfield head fixation device.~Exclusion Criteria:~* Patients under 18 years of age,~* non-English speaking,~* pregnancy,~* opioid tolerance,~* illegal drug use or alcohol abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: EXPERIMENTAL): Intravenous bolus of 10 mL of remifentanil (0.7 mcg/kg based on ideal body weight) will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
- Normal Saline (Type: PLACEBO_COMPARATOR): Intravenous bolus of 10 mL normal saline from study syringe will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults between 18 and 85 years of age~* Diagnosis of acute limb ischemia (defined as an abrupt onset of lower extremity pain with loss of peripheral pulses and absent Doppler pulses in at least one artery and/or ultrasonographic evidence of decreased or absent blood flow to the affected limb) or Diagnosis of critical limb ischemia (defined as resting lower extremity pain with an ABI of \<0.4 and/or ultrasonographic evidence of decreased or absent blood flow to the affected limb).~* Angiographic confirmation of thrombus.~* Need of an intervention within 21 days of the onset of symptoms~Exclusion Criteria:~* Any contraindication for thrombolytic therapy~ABSOLUTE CONTRAINDICATIONS:~A. Any history of intracranial hemorrhage; recent (within three months) hemorrhagic cerebrovascular accident (CVA) / transient ischemic attack (TIA) or significant closed head or facial injury.~B. Known intracranial neoplasm or arteriovenous malformation. C. Suspected aortic dissection. D. Active bleeding diathesis or hemostatic defects: (Excluding menses); active internal~RELATIVE CONTRAINDICATIONS:~Fibrinolytic therapy may be used with the presence of these conditions upon clinical assessment or treatment dependent upon bleeding risks:~A. History of chronic, severe, and poorly controlled blood pressure or Severe uncontrolled hypertension on presentation (SBP \>180, DBP \>110).~B. History of prior ischemic stroke (greater than 3 months) dementia, or known intracranial pathology not covered in absolute contraindications.~C. Traumatic or prolonged CPR (\> 10 minutes), major surgery (\< 3 weeks), or recent trauma, including head trauma (2-4 weeks).~D. Recent (within 2 to 4 weeks) internal bleeding. E. Noncompressible vascular punctures. F. Pregnancy or recent obstetrical delivery. G. Active peptic ulcer disease. H. Anticoagulant use (INR \> 2-3)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CLEARWAY GROUP (Type: ACTIVE_COMPARATOR): Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous in situ thrombolysis (local thrombolytic plus low pressure balloon angioplasty) with Clearway balloon
- ANGIOJET GROUP (Type: ACTIVE_COMPARATOR): Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy with AngioJet Rheolytic Thrombectomy System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-operative or Early Salvage XRT and ADT for High Risk PCa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of prostate cancer~  * Clinical stage cT1-2-3a, N0, M0 disease pre-operatively~ * Pre-operative PSA ≤ 5 x upper limit of normal~* Presenting the following conditions after radical prostatectomy:~  * Gleason sum 5-10~ * Pathologic stage pT2R1 (positive surgical margins with at least a tumor trans-section \> 2 mm) or pT3a-b (irrespective of margin status)~ * Negative lymph node (LN) status (pN0) by LN sampling or LN dissection~    * Unknown pathological LN status is not allowed, except for disease classified as cT ≤ cT1c with baseline PSA ≤ 10 ng/mL, Gleason score \< 7, and ≥ 12 positive core biopsies \< 50%~ * Undetectable post-operative PSA within 3 months of surgery~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* WBC ≥ 3 x 10\^9/L~* Hemoglobin ≥ 110 g/L~* Platelet count ≥ 100 x 10\^9/L~* No other malignancy except adequately treated basal cell carcinoma of the skin or other malignancy from which the patient has been disease free for at least 5 years~* No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 5 years since prior chemotherapy~* No prior pelvic irradiation~* No prior bilateral orchiectomy~* No prior hormonal treatment except neoadjuvant treatment lasting ≤ 3 months~* No other concurrent anticancer agent or modality

- Gender: MALE
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients undergo post-operative conformal external beam irradiation for 6.5 weeks.
- Arm II (Type: EXPERIMENTAL): Beginning on day -5 to -3, patients receive an antiandrogen for 2-4 weeks. Beginning on day 0, patients receive leuprolide acetate subcutaneously once (6-month depot) and undergo conformal external beam irradiation 5 times weekly for 6.5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues